awmsg logo



glecaprevir/pibrentasvir (Maviret®)


Reference No. 3007

Publication date:
19/10/2017


Appraisal information

glecaprevir/pibrentasvir (Maviret®) 100 mg/40 mg film-coated tablet


Company: AbbVie Ltd
BNF category: Infections
NMG meeting date: 06/09/2017
AWMSG meeting date: 11/10/2017
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1917
Ministerial ratification: 18/10/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Glecaprevir/pibrentasvir (Maviret®) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in adults. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download